{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.39","value":"56.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"title":"Baseline Global Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.68","value":"71.48"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"Baseline Emotion Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.34","value":"75.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"Baseline Function Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.94","value":"68.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"title":"Baseline Physical Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.83","value":"88.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"Pre-RT Global Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.35","value":"83.07"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"Pre-RT Emotion Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.96","value":"76.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"Pre-RT Function Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.89","value":"86.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"Pre-RT Physical Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"36.15","value":"62.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Post-RT Global Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.59","value":"67.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Post-RT Emotion Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.62","value":"58.29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"title":"Post-RT Function Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.47","value":"67.81"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Post-RT Physical Score"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"The MD Anderson Dysphasia Inventory (MDADI) is a survey specifically designed to assess dysphasia. It contains 20 questions directly addressing the swallowing function and several other general questions. The questionnaire asks for participants views about their swallowing ability at baseline, pre-radiation therapy and post-radiation therapy. All questions except for E7 and F2: Strongly Agree = 1 point, Agree = 2 points, No Opinion = 3 points, Disagree = 4 points, Strongly Disagree. E7 and F2: Strongly agree = 5 points, Agree = 4 points, no opinion = 3 points, disagree = 2 points, strongly disagree = 1 point. Scores range from 20 (extremely low-functioning) to 100 (high-functioning).","dispersionType":"Standard Deviation","groups":[{"description":"Taxotere/Cisplatinum/5-Fluorouracil (TPF) Chemotherapy Followed by Concomitant Cetuximab \\& Radiation Therapy\n\ncetuximab\n\ncisplatin\n\ndocetaxel\n\nfluorouracil\n\ncomputed tomography\n\npositron emission tomography\n\nquality-of-life assessment\n\n3-dimensional conformal radiation therapy\n\nintensity-modulated radiation therapy","id":"OG000","title":"TPFChemotherapy + Concomitant Cetuximab & RT"}],"paramType":"MEAN","populationDescription":"Data was not collected on all participants","reportingStatus":"POSTED","timeFrame":"Baseline, pre-radiation therapy and post-radiation therapy, up to 2 years","title":"MD Anderson Dysphagia Inventory","type":"SECONDARY","unitOfMeasure":"Score on a scale"}